Novel targets for therapeutic agents in small cell lung cancer

Patrick C. Ma, Ravi Salgia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Small cell lung cancer (SCLC) is known to have an aggressive phenotype and often presents with distant metastasis. Despite frequent initial response to chemotherapy, it inevitably relapses within 2 years in the majority of patients. Because of the poor overall prognosis of the disease and its unique tumor biology, the opportunity for improving clinical outcome of patients with development of novel therapeutics is great. This review provides current insights into the novel molecular targets in SCLC. Cellular signal transduction pathways and their relationship to cellular functions also are discussed. Discussion of the role receptor tyrosine kinases (RTKs) have in SCLC therapeutic inhibition is emphasized. In particular, the recent development of small molecule inhibitors of RTKs such as c-Kit, c-Met, and VEGF-R and the potential for clinical trials are highlighted.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume2
Issue number2
DOIs
StatePublished - Mar 1 2004

Fingerprint

Small Cell Lung Carcinoma
Receptor Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Signal Transduction
Therapeutics
Clinical Trials
Neoplasm Metastasis
Phenotype
Recurrence
Drug Therapy
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{012d869346ad44839af7902f8748cf8e,
title = "Novel targets for therapeutic agents in small cell lung cancer",
abstract = "Small cell lung cancer (SCLC) is known to have an aggressive phenotype and often presents with distant metastasis. Despite frequent initial response to chemotherapy, it inevitably relapses within 2 years in the majority of patients. Because of the poor overall prognosis of the disease and its unique tumor biology, the opportunity for improving clinical outcome of patients with development of novel therapeutics is great. This review provides current insights into the novel molecular targets in SCLC. Cellular signal transduction pathways and their relationship to cellular functions also are discussed. Discussion of the role receptor tyrosine kinases (RTKs) have in SCLC therapeutic inhibition is emphasized. In particular, the recent development of small molecule inhibitors of RTKs such as c-Kit, c-Met, and VEGF-R and the potential for clinical trials are highlighted.",
author = "Ma, {Patrick C.} and Ravi Salgia",
year = "2004",
month = "3",
day = "1",
doi = "10.6004/jnccn.2004.0014",
language = "English (US)",
volume = "2",
pages = "165--172",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "2",

}

Novel targets for therapeutic agents in small cell lung cancer. / Ma, Patrick C.; Salgia, Ravi.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 2, No. 2, 01.03.2004, p. 165-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel targets for therapeutic agents in small cell lung cancer

AU - Ma, Patrick C.

AU - Salgia, Ravi

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Small cell lung cancer (SCLC) is known to have an aggressive phenotype and often presents with distant metastasis. Despite frequent initial response to chemotherapy, it inevitably relapses within 2 years in the majority of patients. Because of the poor overall prognosis of the disease and its unique tumor biology, the opportunity for improving clinical outcome of patients with development of novel therapeutics is great. This review provides current insights into the novel molecular targets in SCLC. Cellular signal transduction pathways and their relationship to cellular functions also are discussed. Discussion of the role receptor tyrosine kinases (RTKs) have in SCLC therapeutic inhibition is emphasized. In particular, the recent development of small molecule inhibitors of RTKs such as c-Kit, c-Met, and VEGF-R and the potential for clinical trials are highlighted.

AB - Small cell lung cancer (SCLC) is known to have an aggressive phenotype and often presents with distant metastasis. Despite frequent initial response to chemotherapy, it inevitably relapses within 2 years in the majority of patients. Because of the poor overall prognosis of the disease and its unique tumor biology, the opportunity for improving clinical outcome of patients with development of novel therapeutics is great. This review provides current insights into the novel molecular targets in SCLC. Cellular signal transduction pathways and their relationship to cellular functions also are discussed. Discussion of the role receptor tyrosine kinases (RTKs) have in SCLC therapeutic inhibition is emphasized. In particular, the recent development of small molecule inhibitors of RTKs such as c-Kit, c-Met, and VEGF-R and the potential for clinical trials are highlighted.

UR - http://www.scopus.com/inward/record.url?scp=17044419172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044419172&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2004.0014

DO - 10.6004/jnccn.2004.0014

M3 - Article

C2 - 19777705

AN - SCOPUS:17044419172

VL - 2

SP - 165

EP - 172

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 2

ER -